▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #6 by analyst upside · 2026-11-13
SBFM
Sunshine Biopharma, Inc.
Healthcare · Market Cap $2M · P/E 0x
ANALYST PRICE TARGET
+39336.6%
implied upside to consensus target
Current Price $2.84
Consensus Target $1120.0
Bull Target $1120.0
Bear Target $1120.0
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $2.53
52-Week High $464.0
YTD Return -98.9%
FUNDAMENTALS
Market Cap $2M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-189.00
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $35M
Profit Margin -16.5%
52-WEEK RANGE
52-Week Low $2.53
52-Week High $464.0
Current Price $2.84
Bear Target $1120.0
Bull Target $1120.0
● Now $2.84 ● Target $1120.0
TRADING DATA
Avg Volume 300K
YTD Return -98.9%
Analyst Count 1
Consensus Buy
Upside to Target +39336.6%
Last Updated 2026-11-13

ANALYST SUMMARY

Sunshine Biopharma, Inc. (SBFM) is currently trading at $2.84 with a Wall Street consensus price target of $1120.0, implying potential upside of 39336.6% over the next 12 months. 1 analysts currently cover SBFM, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1120.0, while the most cautious has a target of $1120.0.

SBFM operates in the Healthcare sector with a market capitalisation of $2M. The stock is down 98.9% year-to-date and is currently trading near the lower end of its 52-week range of $2.53 – $464.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SBFM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Aegis Capital reit
Buy → Buy 2025-10-08 Building track record
Aegis Capital reit
Buy → Buy 2024-12-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →